Nobrega R, et al. - In this study, the clinicians explored the determinants of changes in pain scores and of the percentage of ketamine infusions associated with meaningful changes (≥20% reduction) in pain and opioid consumption in patients with sickle cell disease (SCD) who were taking N-methyl-D-aspartate receptor antagonist, ketamine, as an adjunct to opioids during vaso-occlusive episodes (VOEs). Investigations demonstrated that in SCD patients admitted with VOE-associated pain, ketamine had age- and sex-dependent effects. These findings probably aided in selecting SCD patients. These subjects would benefit most from ketamine.